Akums announces DCGI-approved triple therapy for H. pylori infection

Akums Drugs & Pharmaceuticals has announced the development of a DCGI-approved Clarithromycin + Vonoprazan + Amoxicillin Combikit for the treatment of Helicobacter pylori (H. pylori) infection in adults.

The development is part of the company’s ongoing work in pharmaceutical formulation and reflects the growing focus within healthcare on treatment approaches that consider both therapeutic requirements and the practical aspects of completing a prescribed regimen.

H. pylori infection is associated with chronic gastritis and peptic ulcer disease and is recognised as an important risk factor for gastric cancer. Effective eradication of the infection is therefore an important therapeutic objective and can help reduce infection-related complications.

The combikit combines Vonoprazan, a potassium-competitive acid blocker (P-CAB), with Clarithromycin and Amoxicillin. Vonoprazan provides sustained suppression of gastric acid secretion, while the two antibiotics provide complementary antibacterial action against H. pylori. The prescribed regimen involves twice-daily dosing over a period of 14 days.

The formulation brings the three components together in an organised treatment pack containing Clarithromycin 500 mg, Vonoprazan 20 mg and Amoxicillin 1000 mg. The formulation also provides the full 1000 mg dose of Amoxicillin in one tablet.

Sanjeev Jain, Managing Director, Akums Drugs & Pharmaceuticals said, “Pharmaceutical innovation increasingly needs to consider the complete treatment journey. While scientific development and therapeutic effectiveness remain central, the practical experience of patients undergoing treatment is also an important consideration. Convenience, clarity and the ability to follow a prescribed regimen can influence how treatment is experienced in everyday life. Our work in formulation development is guided by the need to address evolving healthcare requirements through appropriate scientific and pharmaceutical solutions.

Sandeep Jain, Managing Director, Akums Drugs & Pharmaceuticals said, “Developments such as this are enabled by a strong and integrated pharmaceutical ecosystem, where research, formulation development, quality systems and advanced manufacturing capabilities work together. Our focus has been on building capabilities across the pharmaceutical value chain that can support the development and manufacturing of increasingly specialised formulations. A robust manufacturing ecosystem, supported by scientific expertise, is essential to translating pharmaceutical innovation from the development stage into scalable products for the market.”

The announcement comes at a time when the pharmaceutical industry is placing greater emphasis on patient-centred approaches to healthcare. In combination therapies, the organisation and administration of treatment can be an important consideration alongside the therapeutic properties of individual medicines.

For Akums, this development reflects its continued focus on advancing innovative pharmaceutical solutions through its integrated capabilities across research, formulation development, quality and manufacturing. As healthcare requirements continue to evolve, the company remains focused on developing differentiated and innovative formulations across therapeutic areas, leveraging scientific expertise and advanced pharmaceutical technologies to address the needs of pharmaceutical partners, healthcare providers and patients. Going forward, Akums will continue to strengthen its innovation-led approach, translating research and formulation expertise into scalable pharmaceutical solutions that can support evolving healthcare needs.

The post Akums announces DCGI-approved triple therapy for H. pylori infection appeared first on Express Pharma.